Skip to main contentAI and Advanced
/
MEDICAMEQ · NSEBSE SENSEX74,314.59-0.03%BSE |
NIFTY 5023,270.6+0.23%NSE |
NIFTY BANK56,055.75-0.42%NSE |
NIFTY IT29,155.6+0.23%NSE |
NIFTY AUTO27,159.15+0.99%NSE |
NIFTY FMCG45,572.7+0.03%NSE |
NIFTY PHARMA26,579.25+1.66%NSE |
NIFTY 50022,654.65+0.54%NSE |
ME
NSE · Equity shares · Biotechnology & Drugs0.80 · 0.23%
Medicamen Biotech MEDICAMEQ
NSE:INR 346.3
BSE:INR 344.45
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
AI analysis and Advanced tools for MEDICAMEQ
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 345.5
Day rangeINR 290.55 — INR 354.4
52-week rangeINR 212.4 — INR 454
Volume2.49 L
Market cap337.16
P/E28.75
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)197.77
Net Income (INR Cr)9.64
Rev Growth (5 Year %)11.9
EPS Growth (5 Year %)-6.18
P/E Ratio28.75
Book Value202.74
EPS7.22
Price/BV1.71Computed
Research path: Interpret Medicamen Biotech's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
MEDICAMEQMedicamen Biotech1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 371.99 | 297.15 | 294.55 |
| Other Liabilities Total | 2.37 | 2.2 | 1.76 |
| Common Stock Total | 13.56 | 12.71 | 12.71 |
| Other Current Assets Total | 37.9 | 3.09 | 2.88 |
| Total Assets | 371.99 | 297.15 | 294.55 |
| Cash | 31.26 | 3.76 | 14.79 |
| Total Equity | 275.55 | 213.05 | 206.98 |
| Retained Earnings(Accumulated Deficit) | 261.99 | 98.03 | 91.96 |
| Total Common Shares Outstanding | 1.36 | 1.27 | 1.27 |
| Tangible Book Valueper Share Common Eq | 202.74 | 166.98 | 162.9 |
| Total Liabilities | 96.44 | 84.1 | 87.57 |
| Total Debt | 47.78 | 33.77 | 31.11 |
| Cashand Short Term Investments | 31.26 | 3.76 | 14.79 |
| Total Receivables Net | 84.49 | 94.03 | 78.88 |
| Notes Payable/Short Term Debt | 41.63 | 29.52 | 29.56 |
| Accounts Receivable-Trade Net | 81.83 | 68.9 | 55.26 |
| Property/Plant/Equipment Total-Net | 84.09 | 86.36 | 90.95 |
| Total Current Liabilities | 87.92 | 78.16 | 84.56 |
| Total Inventory | 70.08 | 62.15 | 59.83 |
| Accounts Payable | 40.01 | 42.65 | 38.95 |
| Other Currentliabilities Total | 6.28 | 5.47 | 15.75 |
| Total Long Term Debt | 6.15 | 3.73 | 1.26 |
| Intangibles Net | 0.57 | 0.74 | 0.9 |
| Other Long Term Assets Total | 58.63 | 45.5 | 43.11 |
| Note Receivable-Long Term | 4.96 | Not available | Not available |
| Total Current Assets | 223.73 | 164.55 | 159.59 |
| Capital Lease Obligations | 6.15 | 3.73 | 1.26 |
| Accumulated Depreciation Total | Not available | -50.67 | -44 |
| Prepaid Expenses | Not available | 1.52 | 3.22 |
| Current Portof LT Debt/Capital Leases | Not available | 0.52 | 0.29 |
| Additional Paid-In Capital | Not available | 102.31 | 102.31 |
| Property/Plant/Equipment Total-Gross | Not available | 137.03 | 134.96 |
| Deferred Income Tax | Not available | 0 | Not available |
Fundamentals
Valuation and ratios
Growth
Debt 5Yr CAGR %20.49
Margins
Operating Margin 12m6.24
Operating Margin 5y Avg8.8
Net Profit Margin 12m4.95
Net Profit Margin 5y6.97
Yield
Dividend Yield %0.4
Valuation
Price to Sale Ratio1.70
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskHigh risk
Board Risk47.84
Analyst consensus
Analyst consensus unavailable.
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,937.75 | 4.65 L | 38.4 | — |
| Divi's Laboratories | INR 7,376.6 | 1.96 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,976 | 1.68 L | 72.73 | — |
| Cipla | INR 1,410.6 | 1.14 L | 27.57 | — |
| Zydus Lifesciences | INR 1,121.15 | 1.12 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 40.46%
- FII
- 0.07%
- Other
- 59.47%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Medicamen Biotech Ltd is Rated Strong Sell - Markets MojoMarket news · 3 Jun 2026, 2:35 am
Medicamen Biotech Ltd is Rated Strong Sell Markets Mojo
Medicamen Biotech Ltd Reports Strong Quarterly Turnaround Amid Long-Term Challenges - Markets MojoMarket news · 31 May 2026, 1:12 am
Medicamen Biotech Ltd Reports Strong Quarterly Turnaround Amid Long-Term Challenges Markets Mojo
Medicamen Biotech Ltd Valuation Shifts Signal Renewed Price Attractiveness Amid Sector Challenges - Markets MojoMarket news · 29 May 2026, 12:02 am
Medicamen Biotech Ltd Valuation Shifts Signal Renewed Price Attractiveness Amid Sector Challenges Markets Mojo
Medicamen Biotech Ltd is Rated Sell - Markets MojoMarket news · 28 May 2026, 4:05 pm
Medicamen Biotech Ltd is Rated Sell Markets Mojo
Medicamen Biotech Q4 FY26: Strong Quarter Masks Deeper Structural Concerns - Markets MojoMarket news · 28 May 2026, 4:03 pm
Medicamen Biotech Q4 FY26: Strong Quarter Masks Deeper Structural Concerns Markets Mojo
Medicamen Biotech FY26 net profit rises to ₹979.64 lakh - scanx.tradeMarket news · 28 May 2026, 12:30 pm
Medicamen Biotech FY26 net profit rises to ₹979.64 lakh scanx.trade
Corporate actions
Events
- board MeetingsFinal Dividend
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- annual General MeetingAGM
- dividendRs.1.0000 per share(10%)Final Dividend (RD & XD dates revised)
- board MeetingsQuarterly Results
- board MeetingsAudited Results & Final Dividend
- annual General MeetingEGM
Rusaka Markets Community
Discussion and sentiment for Medicamen Biotech
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Medicamen Biotech Limited is an India-based integrated pharmaceutical and life sciences solution provider. The Company is principally engaged in generic finished dosage forms (FDF), Oncology formulations and research and development services to cater to the needs of the global pharmaceutical industry. The Company’s focus areas include antibiotics, hypertension, general pain management, cardiovascular, diabetics and oncology formulations. In cardiology, the Company is delivering effective treatments for heart-related conditions. Its CNS products address neurological disorders, while its diabetology solutions focus on advanced diabetes management. It also contributes to the global fight against malaria with its anti-malarial medications. Additionally, the Company offers essential vitamins, antibiotics for bacterial infections, and comprehensive pain management solutions. Its oncology products include Abiraterone acetate, Anastrozole, Bicalutamide, Bendmustine HCL, and others.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- MEDICAMEQ
- BSE Code
- 531146
Questions
Stock FAQ
What is the symbol and ISIN of Medicamen Biotech?
Medicamen Biotech has the symbol MEDICAMEQ and ISIN - INE646B01010.
What is the current price of Medicamen Biotech?
Medicamen Biotech is currently trading at INR 346.30.
What are the year high and year low of Medicamen Biotech?
Medicamen Biotech has a year high of INR 454.00 and a year low of INR 212.40.
What is the market capitalization of Medicamen Biotech?
Medicamen Biotech has a market capitalization of INR 337.16 crore.
What is the P/E ratio of Medicamen Biotech?
Medicamen Biotech has a P/E ratio of 28.75.
What is the dividend yield of Medicamen Biotech?
Medicamen Biotech has a dividend yield of 0.40%.
How is the financial performance of Medicamen Biotech based on revenue, net income, and EPS?
Medicamen Biotech has revenue of INR 197.77 crore, net income of INR 9.64 crore, and EPS of INR 7.77.
What is the book value of Medicamen Biotech?
Medicamen Biotech has a book value of INR 202.74.
What is the debt-to-equity ratio of Medicamen Biotech?
Medicamen Biotech has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Medicamen Biotech?
Medicamen Biotech has a price-to-book ratio of 1.71 and a price-to-sales ratio of 1.70.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.